Sentences with phrase «based on approved credit»

Rates quoted are based on approved credit.

Based on approved credit, terms and conditions.

Rates subject to change without notice and vary based on approved credit and other factors, such as term, and loan amount.

Financing is based on approved credit thru Fifth Third Bank.

PRICES INCLUDE FINANCE AND TRADE REBATES EVERYONE CAN QUALIFY FOR BASED ON APPROVED CREDIT based on 27886 zip code AND are subject to end without notice plus tax tag and $ 638 admin fee.

Options Includes: Star Safety System, 7» Touch Color Screen Display Audio, AM / FM HD Radio with iPod Connect and Hands Free Phone & Music, Remote Keyless Entry with Push Start, Cruise Control, Power windows Power Door Locks, Halogen Headlamps and Daytime Running Lights, Chrome Tip Exhaust, Color Keyed and Power Exterior Mirrors SETF Lease is based on approved credit of 740 + beacon score qualifier and 12,000 miles a year.

* Financing: Sample payments are based on approved credit.

WOW (requires 760 + credit score and terms may vary or cap, Call us to find out) also must quailify for membership in Credit union area, based on approved credit), It can't get any better than that!

Device pricing may vary based on approved credit; in stores & on customer service calls, upgrade support charge may be required.

Not exact matches

It's important to note that a credit card offer based on a pre-approval does not mean you're already approved.

Getting a home equity loan or line is much like getting a first mortgage; you need to be approved based on the amount of equity in your home and your credit - worthiness.

As a home buyer, your ability to get approved for a mortgage is based on three main factors — your down payment on the home, your current credit score, and your household income relative to your household debt.

The approved purchase price is based on the buyer's personal information, such as income, credit score, and level of savings.

Credit Karma had recommended it to me based on my credit history and a fair chance of me getting APPCredit Karma had recommended it to me based on my credit history and a fair chance of me getting APPcredit history and a fair chance of me getting APPROVED.

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & AcquisiBased on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

Most credit counseling agencies will use the deposit you make on a monthly basis to repay medical bills, student loans, credit cards, and other balances, based on a payment schedule which has been approved by your financial institution.

Today, the Illinois State Senate passed a $ 100 million tax credit scholarship program, and charter funding equity on a bipartisan basis of 38 - 13 votes after the House approved the measure yesterday.

Credit Recovery courses operate on a modified rolling enrollment basis during the fall, spring and summer sessions, with classes starting the Monday after the course has been approved online by the sponsor school's counselor.

Lexus has a stellar reputation for great financing with rates on approved credit from as low as 2.9 % APR with terms up to 84 months based upon vehicle and lender conditions.

Estimated Monthly Payments are based on $ 2500 - $ 3000 down at up to 72 months at 3.99 interest ON APPROVED CREDIT with 750 FICO Score and excellent credit historon $ 2500 - $ 3000 down at up to 72 months at 3.99 interest ON APPROVED CREDIT with 750 FICO Score and excellent credit historON APPROVED CREDIT with 750 FICO Score and excellent credit hiCREDIT with 750 FICO Score and excellent credit hicredit history.

All advertised prices and payments are based on cash prices and on approved credit and exclude government fees and taxes any finance charges any dealer document processing charge any electronic filing charge and any emission testing charge.

* Calculate Payments monthly payment based on 72 month, 4.9 % interest, and $ 2,500 down payment with approved credit.

- IF WE CAN NOT HELP YOU THEN NO ONE CAN - WALK IN and DRIVE OUT TODAY - SOUTHFIELD QUALITY CARS - HOME OF GUARANTEED FINANCING * CALL NOW AND START DRIVING TODAY website www.southfieldqualitycars.com Family Owned Business for 21 Years - Buy with Confidence - We Finance Everyone Guaranteed - First Time Buyer - WE CAN HELP - 100 % Guaranteed Credit Approval - Everyone Approved - No Credit Check Available - Zero Down Plan Available - Get Your Auto Loan Today And Drive - All Trade - Ins Accepted - Drive It Here OR We Tow For Free - Call or Text Today - Payment example based on approximately 10 % down of Total Sale Amount 7.99 % at 72 months.

0 offers may be in lieu of factory rebates, and are based on approved tier 1 credit...

Holmes Honda doesn't discriminate based on credit: you can get approved no matter your financial history at a competitive rate for the area.

This 2014 Nissan Maxima 3.5 SV w / Premium Pkg in Crimson Black Metallic with Black interior comes equipped with NAVIGATON, Bluetooth, Sun / Moonroof, Generic Sun / Moonroof, Power Mirror (s), Integrated Turn Signal Mirrors, Rear Defrost, Intermittent Wipers, Variable Speed Intermittent Wipers, HID headlights, Automatic Headlights, Fog Lamps, AM / FM Stereo, CD Player, Satellite Radio, MP3 Player, Steering Wheel Audio Controls, Bluetooth Connection, Auxiliary Audio Input, Power Driver Seat, Power Passenger Seat, Bucket Seats, Driver Adjustable Lumbar, Pass - Through Rear Seat, Rear Bench Seat, Adjustable Steering Wheel.Lexus has a stellar reputation for great financing with rates on approved credit from as low as 2.9 % APR with terms up to 84 months based upon vehicle and lender conditions.

* Monthly payment based on 20 % Down for 72 months at 6.9 % APR financing On Approved Credion 20 % Down for 72 months at 6.9 % APR financing On Approved CrediOn Approved Credit.

0 % offers may be in lieu of factory rebates, and are based on approved tier 1 credit through NMAC.

Payment based on approved tier 1 credit through NMAC.

Source Capital loans are asset - based, meaning you won't be approved or denied based on your credit score.

Using a proprietary risk model, LendingPoint combines hundreds of data points with algorithms to get a more complete financial story, often leading to approving those who might otherwise have been declined based on their credit score alone.

You are approved for lines of credit up to $ 100,000 based on a variety of factors, which includes linking your financial accounts, like your business checking account, Square, eBay, Amazon or other online accounts, to your application.

It is possible to get a second mortgage in North York, Toronto with bad credit, as the loan is approved based on property equity.

Pre approved offers or otherwise called pre screened offers, are based on information in your credit report that indicates you meet criteria set by the offerer.

Applying individually, Alice would probably not be approved but Bob would get very good terms (in both cases, based on credit history).

The loan is not based on your credit rating, so people with a poor credit rating can still be approved for a mortgage.

The first of these, prequalification, can be done at any time with any lender and the purpose of this step is simply to get a preliminary determination from a lending organization such as a bank, lending company, or credit union that you should be able to get approved for a loan based on your credit score, your income, monthly debt, and additional factors that are considered.

Since traditional loan lenders approve or declined loan based on credit history, lacking credit history implies that they won't approve the loan.

Prior to the CARD Act Some issuers would approve transactions that put accounts over their credit limits and charged over-limit fees on a monthly basis until the cardholder was able to make payments that brought the account under its credit limit.

Most second mortgages are based on equity and not credit, and you can be approved even if you have a poor credit score.

We approve title loans based on the equity of your vehicle, not your credit score.

Each time you use credit card, you are simply borrowing money from your financial institution based on the approved limit set for you.

Answer: Here is a secured credit card option, the Capital One ® Secured Mastercard ®, if approved you will get an initial $ 200 credit line after making a security deposit of $ 49, $ 99 or $ 200, determined based on your creditworthiness.

The approved purchase price is based on the buyer's personal information, such as income, credit score, and level of savings.

Our personal loan approval process is based off of your ability to repay the installment loan and not based on your credit history so you can be approved in minutes, not days!

After your information is submitted, the representative will be able to tell you if the loan was approved based on your credit history, as well as your income information.

Loans are approved based on credit, income and the underwriters» assessment of your risk factor.

Most small business credit cards are approved based on your personal credit score and require your personally guarantee to open an account.

Knowing which cards are open to you based on your credit rating will help your chances of being approved.

While both types of credit are approved based on equity, there are stark differences between them.